New cancer pill tested in patients who ran out of options
NCT ID NCT04648254
Summary
This early-stage study tested the safety and optimal dosing of an experimental oral medication called Q702 in patients with advanced solid tumors. The trial involved 51 adults whose cancers had progressed despite standard treatments or who had no effective standard options available. Researchers monitored side effects, how the drug moved through the body, and preliminary signs of whether it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System Hospital
Morristown, New Jersey, 07960, United States
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Southern California
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.